Many studies on multiple sclerosis (MS) reveal different prevalence and epidemiologic results.
Objectives:
In this study, we aimed to determine the epidemiologic profile of MS using official health records in Turkey.
Methods:
Patients diagnosed with MS from the official health data of the Ministry of Health, representing the entire population of Turkey, were included in the study. Prevalence and incidence calculations were performed using the data on gender, age, year of birth, city of residence, and year of diagnosis.
Results:
As a result of the study, the number of patients with the ICD code G35 was determined as 201,061 and the number of patients with this code entered at least three times was determined as 82,225. The prevalence of MS in Turkey was calculated as 96.4 per 100,000 and the female/male ratio as 2.1/1. The incidence of MS in 2022 was 6.2 per 100,000 and the mean patient age was 43.1 ± 13.3 years (female: 43.0 ± 13.1 vs male: 43.2 ± 13.7) while the mean age at first diagnosis was 34.0 ± 13.0 (female: 33.6 ± 12.6 vs male: 34.9 ± 13.7).
Conclusion:
The research was conducted via Official Database of Turkey, which includes population of 85 million and provides valuable insights into the prevalence and incidence rates of this chronic disease.
NaciHFleurenceRBirtJ, et al. Economic burden of multiple sclerosis. Pharmacoeconomics2010; 28(5): 363–379.
2.
KobeltGThompsonABergJ, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler2017; 23(8): 1123–1136.
3.
ErnstssonOGyllenstenHAlexandersonK, et al. Cost of illness of multiple sclerosis: A systematic review. PLoS ONE2016; 11(7): e0159129.
4.
ChenAYChonghasawatAOLeadholmKL. Multiple sclerosis: Frequency, cost, and economic burden in the United States. J Clin Neurosci2017; 45: 180–186.
5.
PuthenparampilMPeriniPBergamaschiR, et al. Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors. J Neurol2022; 269(4): 1817–1824.
6.
WaltonCKingRRechtmanL, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler2020; 26(14): 1816–1821.
7.
KurtzkeJF. The distribution of multiple sclerosis and other diseases. Acta Neurol Scand1966; 42(2): 221–243.
8.
KurtzkeJF. On the fine structure of the distribution of multiple sclerosis. Acta Neurol Scand1967; 43(3): 257–282.
9.
AhlgrenCOdénALyckeJ. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler2011; 17(8): 901–908.
10.
CantoEOksenbergJR. Multiple sclerosis genetics. Mult Scler2018; 24(1): 75–79.
11.
DisantoGPakpoorJMorahanJM, et al. Epstein-Barr virus, latitude and multiple sclerosis. Mult Scler2013; 19(3): 362–365.
12.
HandelAEHandunnetthiLGiovannoniG, et al. Genetic and environmental factors and the distribution of multiple sclerosis in Europe. Eur J Neurol2010; 17(9): 1210–1214.
13.
HandelAEJarvisLMcLaughlinR, et al. The epidemiology of multiple sclerosis in Scotland: Inferences from hospital admissions. PLoS ONE2011; 6(1): e14606.
14.
McGuiganCMcCarthyAQuigleyC, et al. Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. J Neurol Neurosurg Psychiatry2004; 75(4): 572–576.
15.
RamagopalanSVHandelAEGiovannoniG, et al. Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology2011; 76(16): 1410–1414.
16.
RamagopalanSVHoangUSeagroattV, et al. Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: A descriptive study. J Neurol Neurosurg Psychiatry2011; 82(6): 682–687.
17.
RiscoJMaldonadoHLunaL, et al. Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler2011; 17(9): 1055–1059.
18.
TremlettHZhuFAscherioA, et al. Sun exposure over the life course and associations with multiple sclerosis. Neurology2018; 90(14): e1191–e1199.
19.
XiaoDYeXZhangN, et al. A meta-analysis of interaction between Epstein-Barr virus and HLA-DRB1*1501 on risk of multiple sclerosis. Sci Rep2015; 5: 18083.
20.
BarrieWYangYIrving-PeaseEK, et al. Elevated genetic risk for multiple sclerosis emerged in steppe pastoralist populations. Nature2024; 625(7994): 321–328.
Al-SakranLHMarrieRABlackburnDF, et al. Establishing the incidence and prevalence of multiple sclerosis in Saskatchewan. Can J Neurol Sci2018; 45(3): 295–303.
HawkesCHGiovannoniGLechner ScotJ, et al. Is the incidence of multiple sclerosis really increasing?Mult Scler2020; 45: 102527.
25.
LaneJNgHSPoyserC, et al. Multiple sclerosis incidence: A systematic review of change over time by geographical region. Mult Scler Relat Disord2022; 63: 103932.
26.
ZhangGXCarrillo-VicoAZhangWT, et al. Incidence and prevalence of multiple sclerosis in China and other Asian countries. Neurologia2023; 38(3): 159–172.
27.
BörüÜTBilgiçABKöseoğlu ToksoyC, et al. Prevalence of multiple sclerosis in a Turkish City bordering an iron and steel factory. J Clin Neurol2018; 14(2): 234–241.
28.
Türk BörüÜDumanAKulualpAŞ, et al. Multiple sclerosis prevalence study: The comparison of 3 coastal cities, located in the black sea and mediterranean regions of Turkey. Medicine2018; 97(42): e12856.
29.
GökçeŞFÇiğdemBKaracaSN, et al. Prevalence of multiple sclerosis in an urban population of Sivas province in Turkey. Turk J Med Sci2019; 49(1): 288–294.
30.
AkdemirNTerziMArslanN, et al. Prevalence of multiple sclerosis in the middle black sea region of Turkey and demographic characteristics of patients. Noro Psikiyatr Ars2017; 54(1): 11–14.
31.
ÇelikYBirgiliÖYılmazH, et al. Prevalence of multiple sclerosis in the metropolitan area of Edirne city, Turkey. Balkan Med J2011; 2011(2): 193–196.
32.
Cárdenas-RobledoSLopez-ReyesLArenas-VargasLE, et al. Delayed diagnosis of multiple sclerosis in a low prevalence country. Neurol Res2021; 43(7): 521–527.
33.
PattiFChisariCGArenaS, et al. Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study. Mult Scler Relat Disord2021; 57: 103361.
34.
SteenhofMStenagerENielsenNM, et al. Familial multiple sclerosis patients have a shorter delay in diagnosis than sporadic cases. Mult Scler Relat Disord2019; 32: 97–102.
35.
KantarciOSivaAEraksoyM, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology1998; 51(3): 765–772.
36.
Berg-HansenPMoenSMHarboHF, et al. High prevalence and no latitude gradient of multiple sclerosis in Norway. Mult Scler2014; 20(13): 1780–1782.
37.
VitkovaMDioufIMalpasC, et al. Association of latitude and exposure to ultraviolet B radiation with severity of multiple sclerosis: An International Registry Study. Neurology2022; 98(24): e2401–e2412.
